CYNA (CYNA) Stock Price, News & Analysis

Company Overview

Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson's disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a turning ON medication designed to convert a PD patient from the OFF to the ON state while avoiding the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes. Furthermore, the Company has initiated its pivotal Phase three clinical program for APL-130277.

Key Stats

• Today's Range: $40.48 to $40.48
• 50-Day Range: N/A
• 52-Week Range: $10.54 to $40.67
• Volume: N/A
• Average Volume: 113,889 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CYNA Stock Analysis - Frequently Asked Questions

How were CYNA's earnings last quarter?

CYNA (NASDAQ:CYNA) released its earnings results on Wednesday, August, 10th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by $0.06.

When did CYNA IPO?

CYNA (CYNA) raised $64 million in an initial public offering (IPO) on Thursday, June 18th 2015. The company issued 4,500,000 shares at a price of $14.18 per share. BofA Merrill Lynch served as the underwriter for the IPO and Nomura and Noble Life Science Partners were co-managers.

What other stocks do shareholders of CYNA own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CYNA investors own include Corbus Pharmaceuticals (CRBP), Synthetic Biologics (SYN), 22nd Century Group (XXII), Aralez Pharmaceuticals (ARLZ), RedHill Biopharma (RDHL), Zynerba Pharmaceuticals (ZYNE) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 8/10/2016
• Today: 4/26/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CYNA
• Previous Symbol: OTCMKTS:CYNAF
• CIK: 1532079
• Web: www.cynapsus.ca
• Phone: +1-416-7032449
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A